Slide Show: The Quest for an Effective Ebola Vaccine

Results from an interim analysis of the Guinea Phase III efficacy vaccine trial show that VSV-EBOV (manufactured by Merck, Sharp & Dohme) is highly effective against Ebola. The independent body of international experts - the Data and Safety Monitoring Board – that conducted the review, advised that the trial should continue. Preliminary results from analyses of these interim data are published today in The Lancet. This slide show provides details about the trial and presents a

Register to view the full article

Subscribing to premium content on Infection Control Today will give you access to reports, webinars and other high-value assets.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish